The TAVR 30-day morbidity/mortality composite is a hierarchical, multiple outcome risk model that estimates risk standardized results (reported as a “site difference”) for the purpose of benchmarking site performance. This measure estimates hospital risk standardized site difference for 5 endpoints (death from all causes, stroke, major or life-threatening bleeding, acute kidney injury, moderate or severe paravalvular aortic regurgitation) within 30 days following transcatheter aortic valve replacement. The measure uses clinical data available in the STS/ACC TVT Registry for risk adjustment for the purposes of benchmarking site to site performance on a rolling 3-year timeframe.
A composite outcome including all-cause death, stroke, major or life threatening bleeding, acute kidney injury, moderate or severe paravalvular aortic regurgitation within 30 days following transcatheter aortic valve replacement (TAVR).
If a patient experiences multiple outcomes captured in the overall rank composite measure, the outcome with the highest rank is assigned.
Denominator
1.15 Denominator
Patients who had TAVR.
Exclusions
Exclusions
Hospitals are excluded if they do not meet eligibility criteria noted in S.7. Patients are excluded if any of the following occur: 1) They did not have a first-time TAVR in the episode of care (admission), 2) The TAVR was subsequent to another procedure in the Registry (other TAVR, Mitral Leaflet Clip and/or TMVR) during that admission. 3) The patient is readmitted for a repeat TAVR (re-admission) and the initial TAVR was performed during the rolling 3-year timeframe for the measure. 4) They are in TVT Registry sponsored research studies (identified with research study=yes and research study device used during procedure).
Public Comments